EP3856187 - INFIGRATINIB FOR TREATMENT OF FGFR3-RELATED SKELETAL DISEASES DURING PREGNANCY [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 23.12.2022 Database last updated on 28.06.2024 | |
Former | Request for examination was made Status updated on 02.07.2021 | ||
Former | The international publication has been made Status updated on 05.04.2020 | ||
Former | unknown Status updated on 07.10.2019 | Most recent event Tooltip | 02.02.2024 | Change - applicant | published on 06.03.2024 [2024/10] | Applicant(s) | For all designated states Institut National de la Santé et de la Recherche Médicale (INSERM) 101 rue de Tolbiac 75013 Paris / FR | For all designated states Université Paris Cité 85 boulevard Saint-Germain 75006 Paris / FR | For all designated states ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS 55 boulevard Diderot 75012 Paris 12 / FR | For all designated states Fondation Imagine 24, Boulevard du Montparnasse 75015 Paris / FR | [2024/10] |
Former [2022/32] | For all designated states Institut National de la Santé et de la Recherche Médicale (INSERM) 101 rue de Tolbiac 75013 Paris / FR | ||
For all designated states Université Paris Cité 85 boulevard Saint-Germain 75006 Paris / FR | |||
For all designated states Assistance Publique-Hôpitaux de Paris (APHP) 3, avenue Victoria 75004 Paris / FR | |||
For all designated states Fondation Imagine 24, Boulevard du Montparnasse 75015 Paris / FR | |||
Former [2021/31] | For all designated states Institut National de la Santé et de la Recherche Médicale (INSERM) 101 rue de Tolbiac 75013 Paris / FR | ||
For all designated states Université de Paris 85 boulevard Saint-Germain 75006 Paris / FR | |||
For all designated states Assistance Publique-Hôpitaux de Paris (APHP) 3, avenue Victoria 75004 Paris / FR | |||
For all designated states Fondation Imagine 24, Boulevard du Montparnasse 75015 Paris / FR | Inventor(s) | 01 /
LEGEAI-MALLET, Laurence INSERM U1163 - Institut Imagine 24 Boulevard du Montparnasse 75015 PARIS / FR | [2021/31] | Representative(s) | Lavoix 2, place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | [2021/31] | Application number, filing date | 19778516.5 | 27.09.2019 | [2021/31] | WO2019EP76241 | Priority number, date | EP20180306275 | 28.09.2018 Original published format: EP 18306275 | [2021/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020065034 | Date: | 02.04.2020 | Language: | EN | [2020/14] | Type: | A1 Application with search report | No.: | EP3856187 | Date: | 04.08.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.04.2020 takes the place of the publication of the European patent application. | [2021/31] | Search report(s) | International search report - published on: | EP | 02.04.2020 | Classification | IPC: | A61K31/506, A61P19/00 | [2021/31] | CPC: |
A61K31/506 (EP,US);
A61P19/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/31] | Title | German: | INFIGRATINIB ZUR BEHANDLUNG VON FGFR3-BEDINGTEN SKELETTERKRANKUNGEN WÄHREND DER SCHWANGERSCHAFT | [2021/31] | English: | INFIGRATINIB FOR TREATMENT OF FGFR3-RELATED SKELETAL DISEASES DURING PREGNANCY | [2021/31] | French: | INFIGRATINIB POUR LE TRAITEMENT DE MALADIES DU SQUELETTE ASSOCIÉES À FGFR3 PENDANT LA GROSSESSE | [2021/31] | Entry into regional phase | 25.03.2021 | National basic fee paid | 25.03.2021 | Designation fee(s) paid | 25.03.2021 | Examination fee paid | Examination procedure | 25.03.2021 | Amendment by applicant (claims and/or description) | 25.03.2021 | Examination requested [2021/31] | 25.03.2021 | Date on which the examining division has become responsible | 02.01.2023 | Despatch of a communication from the examining division (Time limit: M06) | 19.06.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 21.09.2021 | Renewal fee patent year 03 | 21.09.2022 | Renewal fee patent year 04 | 20.09.2023 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2015011560 (LEGEAI-MALLET LAURENCE [FR]) [A] 1-6 * claims 1-3 ** examples 7-8 * | by applicant | - KOMLA-EBRI, D.DAMBROISE, E.KRAMER, I.BENOIST-LASSELIN, C.KACI, N.LE GALL, C.KNEISSEL, M., "Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model", The Journal of clinical investigation, (20160000), vol. 126, no. 5, doi:doi:10.1172/JCI83926, pages 1871 - 1884, XP009512233 DOI: http://dx.doi.org/10.1172/JCI83926 | - BIOSSE DUPLAN, M.KOMLA-EBRI, D.HEUZE, Y.ESTIBALS, V.GAUDAS, E.KACI, N.PORTA, D. G., "Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible", Human molecular genetics, (20160000), vol. 25, no. 14, pages 2997 - 3010 | - PANNIER, S.COULOIGNER, V.MESSADDEQ, N.ELMALEH-BERGES, M.MUNNICH, A.ROMAND, R.LEGEAI-MALLET, L., "Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia", Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, (20090000), vol. 1792, no. 2, doi:doi:10.1016/j.bbadis.2008.11.010, pages 140 - 147, XP025884358 DOI: http://dx.doi.org/10.1016/j.bbadis.2008.11.010 |